Compounds for targeting cancer stem cells
AssigneeThe General Hospital Corporation
InventorsIgor Garkavtsev, Rakesh K. Jain
Life of this patent
Estimating the term…
Abstract
This invention relates to antagonists of G3BP2, G3BP1, and ZEB1. Pharmaceutical compositions comprising G3BP2 inhibitors, methods of inhibiting G3BP2, G3BP1, and ZEB1, methods of treating cancer and inflammation, and methods of identifying an inhibitor of cancer stems cells are also provided.
Claims9
A method of treating a breast cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A method of reducing metastasis of a breast cancer in a patient, the method comprising administering to the patient in need thereof a therapeutically effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating a breast cancer in a patient, the method comprising:
- i) identifying the patient as having a breast cancer selected from:
- breast cancer associated with overexpression of G3BP2, breast cancer associated with overexpression of ZEB1, breast cancer associated with overexpression of G3BP2 and overexpression of ZEB1, breast cancer associated with overexpression of G3BP1, breast cancer associated with overexpression of G3BP1 and overexpression of G3BP2, and breast cancer associated with overexpression of G3BP1, overexpression of G3BP2, and overexpression of ZEB1;
- and
- ii) administering to the patient a therapeutically effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A method of inhibiting G3BP1, G3BP2, or ZEB1, or any combination thereof, in a breast cancer cell, the method comprising contacting the breast cancer cell with an effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A method of inhibiting growth of a breast cancer stem cell, the method comprising contacting the breast cancer stem cell with an effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.